29 Participants Needed

WT1-specific T Cells for Multiple Myeloma

Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests the safety of special white blood cells from a donor that are trained to attack a protein made by multiple myeloma cancer cells. The goal is to see if these cells can effectively kill the cancer cells and understand their effects on patients.

Who Is on the Research Team?

SG

Sergio Giralt, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults aged 21-73 with relapsed multiple myeloma post-autologous stem cell transplant or plasma cell leukemia at diagnosis. Participants need a matched donor for T-cell depleted stem cell transplant, good organ function, and a performance status >70%. Pregnant women, those with active infections or other malignancies not in remission, HIV/HTLV-positive individuals, and those allergic to mouse proteins or chicken eggs are excluded.

Inclusion Criteria

My heart, liver, kidneys, and lungs are all functioning well.
My gender or ethnic background does not limit my participation.
My multiple myeloma has returned or didn't respond after a stem cell transplant.
See 7 more

Exclusion Criteria

You have tested positive for HIV or HTLV.
I have had cancer before that is not currently in remission.
I am not pregnant or breastfeeding.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Preparative Regimen and Transplantation

Patients undergo a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), followed by a T cell depleted stem cell transplant from a histocompatible donor.

3-4 weeks

WT1-specific T Cell Infusion

Administration of WT1-specific cytotoxic T cells post transplantation to induce complete remissions and decrease relapse rate.

3 weeks

Follow-up

Participants are monitored for safety, effectiveness, and serologic responses after treatment, including toxicities and survival.

2 years

What Are the Treatments Tested in This Trial?

Interventions

  • WT1-specific Donor-derived T Cells
Trial Overview The study tests the safety of different doses of WT1-specific donor-derived T cells after a T-cell depleted allogeneic hematopoietic stem cell transplantation. These lab-grown white cells target the Wilms' tumor protein (WT1) expressed by myeloma cells to see if they can effectively kill them.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Pts with Mutiple myelomaExperimental Treatment5 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security